[{"address1": "60 Leveroni Court", "city": "Novato", "state": "CA", "zip": "94949", "country": "United States", "phone": "415 483 8800", "website": "https://www.ultragenyx.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.", "fullTimeEmployees": 1276, "companyOfficers": [{"maxAge": 1, "name": "Dr. Emil D. Kakkis M.D., Ph.D.", "age": 63, "title": "Founder, President, CEO & Director", "yearBorn": 1960, "fiscalYear": 2023, "totalPay": 1459548, "exercisedValue": 1272193, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Howard  Horn", "age": 45, "title": "Executive VP of Corporate Strategy & CFO", "yearBorn": 1978, "fiscalYear": 2023, "totalPay": 184808, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Karah Herdman Parschauer J.D.", "age": 45, "title": "Chief Legal Officer & Executive VP of Corporate Affairs", "yearBorn": 1978, "fiscalYear": 2023, "totalPay": 846744, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. John Richard Pinion II", "age": 57, "title": "Chief Quality Operations Officer & Executive VP of Translational Sciences", "yearBorn": 1966, "fiscalYear": 2023, "totalPay": 860053, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Erik  Harris", "age": 52, "title": "Executive VP & Chief Commercial Officer", "yearBorn": 1971, "fiscalYear": 2023, "totalPay": 878767, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Theodore A. Huizenga", "age": 52, "title": "Senior VP, Corporate Controller & Principal Accounting Officer", "yearBorn": 1971, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Ernie W. Meyer", "age": 58, "title": "Chief Human Resources Officer & Executive VP", "yearBorn": 1965, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Thomas R. Kassberg", "age": 63, "title": "Chief Business Officer & Executive VP", "yearBorn": 1960, "fiscalYear": 2023, "totalPay": 714838, "exercisedValue": 0, "unexercisedValue": 6082348}, {"maxAge": 1, "name": "Mr. Vimal  Srivastava", "age": 58, "title": "Senior Vice President of Business Development & Alliance Management", "yearBorn": 1965, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Dennis Karl Huang", "age": 58, "title": "Chief Technical Operations Officer and Executive VP of Gene Therapy Research & Development", "yearBorn": 1965, "fiscalYear": 2023, "totalPay": 331330, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 2, "boardRisk": 1, "compensationRisk": 9, "shareHolderRightsRisk": 7, "overallRisk": 6, "governanceEpochDate": 1725148800, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 56.12, "open": 56.4, "dayLow": 55.64, "dayHigh": 57.26, "regularMarketPreviousClose": 56.12, "regularMarketOpen": 56.4, "regularMarketDayLow": 55.64, "regularMarketDayHigh": 57.26, "beta": 0.567, "forwardPE": -10.961165, "volume": 667667, "regularMarketVolume": 667667, "averageVolume": 883408, "averageVolume10days": 676140, "averageDailyVolume10Day": 676140, "bid": 56.41, "ask": 56.59, "bidSize": 100, "askSize": 100, "marketCap": 5202725376, "fiftyTwoWeekLow": 31.52, "fiftyTwoWeekHigh": 58.73, "priceToSalesTrailing12Months": 10.809668, "fiftyDayAverage": 47.9368, "twoHundredDayAverage": 45.4154, "currency": "USD", "enterpriseValue": 5331374080, "profitMargins": -1.2157, "floatShares": 88831493, "sharesOutstanding": 92165200, "sharesShort": 3847176, "sharesShortPriorMonth": 4362643, "sharesShortPreviousMonthDate": 1721001600, "dateShortInterest": 1723680000, "sharesPercentSharesOut": 0.0417, "heldPercentInsiders": 0.03658, "heldPercentInstitutions": 0.99068, "shortRatio": 5.02, "shortPercentOfFloat": 0.0479, "bookValue": 4.697, "priceToBook": 12.01831, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -585121024, "trailingEps": -7.21, "forwardEps": -5.15, "pegRatio": -0.24, "lastSplitFactor": "1:3", "lastSplitDate": 1389916800, "enterpriseToRevenue": 11.077, "enterpriseToEbitda": -10.337, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "RARE", "underlyingSymbol": "RARE", "shortName": "Ultragenyx Pharmaceutical Inc.", "longName": "Ultragenyx Pharmaceutical Inc.", "firstTradeDateEpochUtc": 1391178600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "b052b015-0bd3-3428-acad-e3223ac2e5e2", "gmtOffSetMilliseconds": -14400000, "currentPrice": 56.45, "targetHighPrice": 140.0, "targetLowPrice": 46.0, "targetMeanPrice": 89.8, "targetMedianPrice": 79.0, "recommendationMean": 1.7, "recommendationKey": "buy", "numberOfAnalystOpinions": 20, "totalCash": 763820992, "totalCashPerShare": 8.293, "ebitda": -515737984, "totalDebt": 926536000, "quickRatio": 3.196, "currentRatio": 3.535, "totalRevenue": 481303008, "debtToEquity": 214.269, "revenuePerShare": 5.946, "returnOnAssets": -0.23417, "returnOnEquity": -2.08433, "freeCashflow": -275984736, "operatingCashflow": -469468000, "revenueGrowth": 0.357, "grossMargins": -0.4952, "ebitdaMargins": -1.07155, "operatingMargins": -0.79143, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-09-05"}]